{"id":5068,"date":"2026-02-24T20:38:14","date_gmt":"2026-02-24T20:38:14","guid":{"rendered":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/"},"modified":"2026-02-24T20:38:14","modified_gmt":"2026-02-24T20:38:14","slug":"healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss","status":"publish","type":"post","link":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/","title":{"rendered":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p><em>A version of this article first appeared in CNBC&#8217;s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. <\/em><a href=\"https:\/\/www.cnbc.com\/healthy-returns-newsletter\/\"><em>Subscribe here<\/em><\/a><em> to receive future editions.<\/em><\/p>\n<p>Novo Nordisk isn&#8217;t <a href=\"https:\/\/www.cnbc.com\/2026\/02\/11\/novo-nordisk-faces-defining-year-in-the-obesity-drug-market.html\">catching a break<\/a> this year.\u00a0<\/p>\n<p>Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug <a href=\"https:\/\/www.cnbc.com\/2026\/02\/23\/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html\">failed to match the weight loss <\/a>of <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"SpecialReportArticle-QuoteInBody-4\"><a href=\"https:\/\/www.cnbc.com\/quotes\/LLY\/\">Eli Lilly<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>&#8216;s Zepbound in a phase three trial.\u00a0<\/p>\n<p>The results showed that Novo&#8217;s drug, CagriSema, promoted slightly less weight loss than Zepbound at 84 weeks in the study \u2014 a difference that puts the sales potential of the experimental treatment into question. Analysts all raise the same point: Why would patients or doctors choose Novo&#8217;s drug over a more effective and widely-known choice like Zepbound?\u00a0<\/p>\n<p>&#8220;We struggle to identify a reason why a patient would be prescribed CagriSema&#8221; instead of Zepbound if the product comes to market, said BMO analyst Evan Seigerman in a Monday note.\u00a0<\/p>\n<p>In a separate note on Monday, JPMorgan analyst Chris Schott said the results &#8220;will make it difficult for the product to gain [market] share&#8221; from Lilly. If anything, it confirms Zepbound as a &#8220;clear market leader&#8221; and positions Lilly to gain even more market share, he added.\u00a0<\/p>\n<p>Still, Novo isn&#8217;t giving up on the product.\u00a0<\/p>\n<p>It&#8217;s too late anyway: the company already filed for Food and Drug Administration approval of CagriSema, with a decision expected in late 2026. That means that the drug could launch by the end of the year or early 2027.\u00a0<\/p>\n<p>&#8220;To say it&#8217;s obsolete is quite belittling a fantastic drug, in all honesty,&#8221; Novo&#8217;s CEO Mike Doustdar told analysts on Monday, brushing off concerns about CagriSema&#8217;s commercial potential. He said he believes the drug has better weight loss efficacy than anything on the market.\u00a0<\/p>\n<p>Novo is &#8220;pleased&#8221; with the 23% weight loss that CagriSema caused, which shows that it offers &#8220;clinically meaningful additive weight loss effects&#8221; that are superior to what&#8217;s been seen with drugs that only target GLP-1, Chief Scientific Officer Martin Holst Lange said in a release on Monday. That includes semaglutide, the active ingredient in Novo&#8217;s existing obesity injection Wegovy. CagriSema combines semaglutide and cagrilintide, another hormone released in the pancreas that affects appetite.<\/p>\n<p>Lilly&#8217;s Zepound helped people lose around 25% of their weight in the trial, but Doustdar called that an &#8220;abnormality&#8221; that has not been seen in any other studies.\u00a0<\/p>\n<p>Novo is also pinning its hopes on other upcoming trials to show CagriSema&#8217;s full weight loss potential.\u00a0<\/p>\n<p>That includes the REDEFINE 11 trial, a phase three study that will compare CagriSema to a placebo in 600 adults with obesity. The initial results from that trial are expected in the first half of 2027.<\/p>\n<p>But Novo has much to prove to Wall Street. BMO&#8217;s Seigerman said he&#8217;s not convinced that the upcoming trial &#8220;is going to change the narrative around CagriSema.&#8221;<\/p>\n<p>Novo also expects to begin a phase three trial investigating a higher dose of CagriSema in the second half of 2026. On the call with analysts, Doustdar suggested that the greater efficacy seen with a higher dose of Wegovy could translate to CagriSema.\u00a0<\/p>\n<p>The standard doses of Wegovy cause around 15% to 16% weight loss, while the high dose comes closer to 21%, he said.\u00a0<\/p>\n<p>Regardless of how CagriSema performs, Novo needs to find a strong competitor to Lilly&#8217;s drugs. Zepbound&#8217;s higher efficacy has allowed it to win significant market share, and Lilly is planning to launch a next-generation obesity drug that targets three gut hormones and has promoted more than 28% weight loss in clinical trials.\u00a0<\/p>\n<p>Novo last year <a href=\"https:\/\/www.cnbc.com\/2025\/03\/25\/healthy-returns-novo-nordisk-buys-united-laboratories-obesity-drug.html\">paid $2 billion for the rights<\/a> to a Chinese drugmaker&#8217;s experimental medicine, which works in the same way as Lilly&#8217;s upcoming treatment.\u00a0<\/p>\n<p>However, with Novo&#8217;s product still in early-stage development, M&amp;A could offer a faster path forward.<\/p>\n<p>Doustdar <a href=\"https:\/\/www.cnbc.com\/2026\/01\/14\/healthy-returns-novo-nordisk-ceo-glp-1-pill-jpmorgan-conference.html\">told me in January<\/a> that Novo plans to be an active dealmaker to &#8220;see if anyone else out there has something that can complement our own pipeline.&#8221;<\/p>\n<p>Feel free to send any tips, suggestions, story ideas and data to Annika at a new email: <a href=\"http:\/\/annika.constantino@versantmedia.com\" target=\"_blank\">annika.constantino@versantmedia.com<\/a>.<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.cnbc.com\/2026\/02\/24\/healthy-returns-whats-next-for-novo-nordisks-obesity-drug-cagrisema.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A version of this article first appeared in CNBC&#8217;s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn&#8217;t catching a break this year.\u00a0 Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":5069,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080","fifu_image_alt":"","footnotes":""},"categories":[4],"tags":[73,77,488,70,3999,259,2606,65],"class_list":["post-5068","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-biotech-and-pharmaceuticals","tag-business-news","tag-eli-lilly-and-co","tag-health-care-industry","tag-ishares-u-s-pharmaceuticals-etf","tag-novo-nordisk-a-s","tag-robert-f-kennedy-jr","tag-social-issues"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.8 (Yoast SEO v22.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss - Breaking News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss\" \/>\n<meta property=\"og:description\" content=\"A version of this article first appeared in CNBC&#8217;s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn&#8217;t catching a break this year.\u00a0 Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed...Read More &ldquo;Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss&rdquo; &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Breaking News\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T20:38:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\"},\"headline\":\"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss\",\"datePublished\":\"2026-02-24T20:38:14+00:00\",\"dateModified\":\"2026-02-24T20:38:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\"},\"wordCount\":690,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"keywords\":[\"Biotech and Pharmaceuticals\",\"business news\",\"Eli Lilly and Co\",\"Health care industry\",\"iShares U.S. Pharmaceuticals ETF\",\"Novo Nordisk A\/S\",\"Robert F. Kennedy Jr.\",\"Social issues\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\",\"url\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\",\"name\":\"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss - Breaking News\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#website\"},\"datePublished\":\"2026-02-24T20:38:14+00:00\",\"dateModified\":\"2026-02-24T20:38:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ventil.rs\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ventil.rs\/blog\/#website\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"name\":\"Breaking News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ventil.rs\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\",\"name\":\"Breaking News\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"contentUrl\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"width\":1445,\"height\":591,\"caption\":\"Breaking News\"},\"image\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"sameAs\":[\"https:\/\/ventil.rs\/blog\"],\"url\":\"https:\/\/ventil.rs\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss - Breaking News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/","og_locale":"en_US","og_type":"article","og_title":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss","og_description":"A version of this article first appeared in CNBC&#8217;s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn&#8217;t catching a break this year.\u00a0 Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed...Read More &ldquo;Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss&rdquo; &raquo;","og_url":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/","og_site_name":"Breaking News","article_published_time":"2026-02-24T20:38:14+00:00","og_image":[{"url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080","twitter_misc":{"Written by":"Admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#article","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/"},"author":{"name":"Admin","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a"},"headline":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss","datePublished":"2026-02-24T20:38:14+00:00","dateModified":"2026-02-24T20:38:14+00:00","mainEntityOfPage":{"@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/"},"wordCount":690,"commentCount":0,"publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"keywords":["Biotech and Pharmaceuticals","business news","Eli Lilly and Co","Health care industry","iShares U.S. Pharmaceuticals ETF","Novo Nordisk A\/S","Robert F. Kennedy Jr.","Social issues"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/ventil.rs\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/","url":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/","name":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss - Breaking News","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/#website"},"datePublished":"2026-02-24T20:38:14+00:00","dateModified":"2026-02-24T20:38:14+00:00","breadcrumb":{"@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ventil.rs\/blog\/health\/healthy-returns-whats-next-for-novo-nordisks-next-generation-obesity-drug-cagrisema-after-trial-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ventil.rs\/blog\/"},{"@type":"ListItem","position":2,"name":"Healthy Returns: What\u2019s next for Novo Nordisk\u2019s next-generation obesity drug CagriSema after trial miss"}]},{"@type":"WebSite","@id":"https:\/\/ventil.rs\/blog\/#website","url":"https:\/\/ventil.rs\/blog\/","name":"Breaking News","description":"","publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ventil.rs\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ventil.rs\/blog\/#organization","name":"Breaking News","url":"https:\/\/ventil.rs\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","contentUrl":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","width":1445,"height":591,"caption":"Breaking News"},"image":{"@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","caption":"Admin"},"sameAs":["https:\/\/ventil.rs\/blog"],"url":"https:\/\/ventil.rs\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/comments?post=5068"}],"version-history":[{"count":0,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5068\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media\/5069"}],"wp:attachment":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media?parent=5068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/categories?post=5068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/tags?post=5068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}